# BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 Q1 P&L / Income Statement - Company: BOSTON SCIENTIFIC CORPORATION (BSX) - Period: 2026-01-01 to 2026-03-31 - Filing: Q1 FY2026 10-Q, filed 2026-05-01, accession number 0000885725-26-000033 - Page: https://plicit.ai/financials/bsx/fy2026-q1-income-statement - Chart image: https://plicit.ai/charts/bsx-fy2026-q1-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2026-01-01 through 2026-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 5,203,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 1,590,000,000 US dollars - **Gross profit**: 3,614,000,000 US dollars - **Operating expenses**: 2,513,000,000 US dollars - **Operating income (loss)**: 1,101,000,000 US dollars - **Other income (expense), net (calculated)**: 61,000,000 US dollars - **Income (loss) before income taxes**: 1,162,000,000 US dollars - **Income tax expense (benefit)**: negative 176,000,000 US dollars - **Net income (loss)**: 1,339,000,000 US dollars - **Cardiac Rhythm Management - UNITED STATES**: 349,000,000 US dollars - **Cardiac Rhythm Management - Int'l**: 229,000,000 US dollars - **Electrophysiology - UNITED STATES**: 603,000,000 US dollars - **Electrophysiology - Int'l**: 302,000,000 US dollars - **Endoscopy - UNITED STATES**: 446,000,000 US dollars - **Endoscopy - Int'l**: 290,000,000 US dollars - **Neuromodulation - UNITED STATES**: 236,000,000 US dollars - **Neuromodulation - Int'l**: 82,000,000 US dollars - **Urology - UNITED STATES**: 465,000,000 US dollars - **Urology - Int'l**: 182,000,000 US dollars - **Interventional Cardiology & Vascular Therapies - UNITED STATES**: 552,000,000 US dollars - **Interventional Cardiology & Vascular Therapies - Int'l**: 692,000,000 US dollars - **Interventional Oncology & Embolization - UNITED STATES**: 170,000,000 US dollars - **Interventional Oncology & Embolization - Int'l**: 99,000,000 US dollars - **Watchman - UNITED STATES**: 462,000,000 US dollars - **Watchman - Int'l**: 44,000,000 US dollars - **Selling, general and administrative expenses**: 1,781,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 516,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Royalty expense**: 12,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Amortization expense**: 232,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Contingent consideration net expense (benefit)**: negative 30,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Restructuring net charges (credits)**: 3,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $1.34 B; to noncontrolling interests: −$2.00 M. - The amounts that make up gross profit come to $3,613.00 M and gross profit is $3,614.00 M; the $1.00 M difference is within the rounding of the filed amounts. - The amounts that make up net income come to $1,338.00 M and net income is $1,339.00 M; the $1.00 M difference is within the rounding of the filed amounts. ## Chart details: Revenue by Business Segment - Page: https://plicit.ai/financials/bsx/fy2026-q1-income-statement/revenue-by-business-segment - Chart image: https://plicit.ai/charts/bsx-fy2026-q1-revenue-by-business-segment-sankey.png Income statement for 2026-01-01 through 2026-03-31. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 5,203,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 1,590,000,000 US dollars - **Gross profit**: 3,614,000,000 US dollars - **Operating expenses**: 2,513,000,000 US dollars - **Operating income (loss)**: 1,101,000,000 US dollars - **Other income (expense), net (calculated)**: 61,000,000 US dollars - **Income (loss) before income taxes**: 1,162,000,000 US dollars - **Income tax expense (benefit)**: negative 176,000,000 US dollars - **Net income (loss)**: 1,339,000,000 US dollars - **MedSurg**: 1,701,000,000 US dollars - **Cardiovascular**: 3,503,000,000 US dollars - **Selling, general and administrative expenses**: 1,781,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 516,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Royalty expense**: 12,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Amortization expense**: 232,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Contingent consideration net expense (benefit)**: negative 30,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Restructuring net charges (credits)**: 3,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Revenue before reconciliation (calculated)**: 5,204,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $1.34 B; to noncontrolling interests: −$2.00 M. - The amounts that make up gross profit come to $3,613.00 M and gross profit is $3,614.00 M; the $1.00 M difference is within the rounding of the filed amounts. - The amounts that make up net income come to $1,338.00 M and net income is $1,339.00 M; the $1.00 M difference is within the rounding of the filed amounts. ## Chart details: Revenue by Business Segment by Geography - Page: https://plicit.ai/financials/bsx/fy2026-q1-income-statement/revenue-by-business-segment-by-geography - Chart image: https://plicit.ai/charts/bsx-fy2026-q1-revenue-by-business-segment-by-geography-sankey.png Income statement for 2026-01-01 through 2026-03-31. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 5,203,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 1,590,000,000 US dollars - **Gross profit**: 3,614,000,000 US dollars - **Operating expenses**: 2,513,000,000 US dollars - **Operating income (loss)**: 1,101,000,000 US dollars - **Other income (expense), net (calculated)**: 61,000,000 US dollars - **Income (loss) before income taxes**: 1,162,000,000 US dollars - **Income tax expense (benefit)**: negative 176,000,000 US dollars - **Net income (loss)**: 1,339,000,000 US dollars - **BSX Reportable Segments - Latin America and Canada**: 185,000,000 US dollars - **BSX Reportable Segments - Asia-Pacific**: 803,000,000 US dollars - **BSX Reportable Segments - Europe, Middle East and Africa**: 932,000,000 US dollars - **Cardiovascular - UNITED STATES**: 2,137,000,000 US dollars - **Cardiovascular - Int'l**: 1,366,000,000 US dollars - **MedSurg - UNITED STATES**: 1,147,000,000 US dollars - **MedSurg - Int'l**: 554,000,000 US dollars - **Selling, general and administrative expenses**: 1,781,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 516,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Royalty expense**: 12,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Amortization expense**: 232,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Contingent consideration net expense (benefit)**: negative 30,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Restructuring net charges (credits)**: 3,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Revenue before reconciliation (calculated)**: 7,124,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 1,921,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $1.34 B; to noncontrolling interests: −$2.00 M. - The amounts that make up gross profit come to $3,613.00 M and gross profit is $3,614.00 M; the $1.00 M difference is within the rounding of the filed amounts. - The amounts that make up net income come to $1,338.00 M and net income is $1,339.00 M; the $1.00 M difference is within the rounding of the filed amounts. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/bsx/fy2026-q1-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/bsx-fy2026-q1-revenue-by-geography-sankey.png Income statement for 2026-01-01 through 2026-03-31. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 5,203,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 1,590,000,000 US dollars - **Gross profit**: 3,614,000,000 US dollars - **Operating expenses**: 2,513,000,000 US dollars - **Operating income (loss)**: 1,101,000,000 US dollars - **Other income (expense), net (calculated)**: 61,000,000 US dollars - **Income (loss) before income taxes**: 1,162,000,000 US dollars - **Income tax expense (benefit)**: negative 176,000,000 US dollars - **Net income (loss)**: 1,339,000,000 US dollars - **UNITED STATES**: 3,284,000,000 US dollars - **Int'l**: 1,920,000,000 US dollars - **Selling, general and administrative expenses**: 1,781,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 516,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Royalty expense**: 12,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Amortization expense**: 232,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Contingent consideration net expense (benefit)**: negative 30,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Restructuring net charges (credits)**: 3,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Revenue before reconciliation (calculated)**: 5,204,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $1.34 B; to noncontrolling interests: −$2.00 M. - The amounts that make up gross profit come to $3,613.00 M and gross profit is $3,614.00 M; the $1.00 M difference is within the rounding of the filed amounts. - The amounts that make up net income come to $1,338.00 M and net income is $1,339.00 M; the $1.00 M difference is within the rounding of the filed amounts. ## Chart details: Revenue by Product and Service - Page: https://plicit.ai/financials/bsx/fy2026-q1-income-statement/revenue-by-product-and-service - Chart image: https://plicit.ai/charts/bsx-fy2026-q1-revenue-by-product-and-service-sankey.png Income statement for 2026-01-01 through 2026-03-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Net sales**: 5,203,000,000 US dollars - **Cost of products sold (excluding amortization expense)**: 1,590,000,000 US dollars - **Gross profit**: 3,614,000,000 US dollars - **Operating expenses**: 2,513,000,000 US dollars - **Operating income (loss)**: 1,101,000,000 US dollars - **Other income (expense), net (calculated)**: 61,000,000 US dollars - **Income (loss) before income taxes**: 1,162,000,000 US dollars - **Income tax expense (benefit)**: negative 176,000,000 US dollars - **Net income (loss)**: 1,339,000,000 US dollars - **Endoscopy**: 736,000,000 US dollars - **Urology**: 646,000,000 US dollars - **Neuromodulation**: 318,000,000 US dollars - **Interventional Cardiology & Vascular Therapies**: 1,244,000,000 US dollars - **Watchman**: 506,000,000 US dollars - **Electrophysiology**: 905,000,000 US dollars - **Cardiac Rhythm Management**: 578,000,000 US dollars - **Interventional Oncology & Embolization**: 268,000,000 US dollars - **Undisclosed (calculated)**: 2,000,000 US dollars - **Selling, general and administrative expenses**: 1,781,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Research and development expenses**: 516,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Royalty expense**: 12,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Amortization expense**: 232,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Contingent consideration net expense (benefit)**: negative 30,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. - **Restructuring net charges (credits)**: 3,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Of which attributable to BOSTON SCIENTIFIC CORPORATION: $1.34 B; to noncontrolling interests: −$2.00 M. - The amounts that make up gross profit come to $3,613.00 M and gross profit is $3,614.00 M; the $1.00 M difference is within the rounding of the filed amounts. - The amounts that make up net income come to $1,338.00 M and net income is $1,339.00 M; the $1.00 M difference is within the rounding of the filed amounts.